Status:
RECRUITING
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Lead Sponsor:
University of Manitoba
Conditions:
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect...
Detailed Description
RATIONALE: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Despite the best efforts of their care team, patients with MDS and AML commonly ex...
Eligibility Criteria
Inclusion
- Master platform inclusion criteria:
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndromes or acute myeloid leukemia
- MYELO-CAN TXA inclusion criteria:
- Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting)
- Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation)
Exclusion
- Master platform exclusion criteria:
- Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
- Participant unable to provide informed consent
- MYELO-CAN TXA exclusion criteria:
- Known allergy to tranexamic acid
- Active thromboembolic disease
- Active ischemic heart disease
- Gross hematuria
- Stage V chronic kidney disease
- Clinically suspected disseminated intravascular coagulation (DIC)
- Pregnancy and/or breastfeeding
Key Trial Info
Start Date :
September 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06599762
Start Date
September 10 2025
End Date
April 1 2027
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9